Still, despite the numerous promising biomarkers identified so far only interferon-gamma (IFN-γ) release assays (IGRA) currently exist in clinical practice, but IGRAs do not distinguish active TB from LTBI (22) and are not useful in high burden settings (23). This evidence concerns the gene IFNG and tuberculosis.